ContraFect’s Exebacase Receives the US FDA’s Breakthrough Therapy Designation for MRSA Bacteremia including Right-Sided Endocarditis

 ContraFect’s Exebacase Receives the US FDA’s Breakthrough Therapy Designation for MRSA Bacteremia including Right-Sided Endocarditis

ContraFect’s Exebacase Receives the US FDA’s Breakthrough Therapy Designation for MRSA Bacteremia including Right-Sided Endocarditis

Shots:

  • The BTD is based on P-II superiority trial assessing Exebacase + SOC antibiotic therapy vs SOC alone in patients with Staphylococcus aureus bacteremia, including endocarditis
  • In a pre-specified analysis of the subgroup with MRSA infections, the clinical responder rate @day14 (74.1% vs 31.3%). The Exebacase demonstrated a reduction in the 30-day all-cause mortality, 4days reduction in length of hospital stay, and reductions in 30-day hospital readmission rates in MRSA-infected patients
  • Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Exelixis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post